Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CETIRIZINE HYDROCHLORIDE

All products: not a benefit

Other products in the same Health Canada class (R06A) — coverage varies; not interchangeable

  • Bilastine (Jamp Bilastine Oral Solution): not a benefit
  • Loratadine (Claritin): not a benefit
  • Rupatadine (Rupall): not a benefit

Apo-Cetirizine · DIN 02231603 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Cetirizine · DIN 02231603 Manufacturer: Apotex Inc.; listing date 2007-12-19 Health Canada: Marketed since 1998-10-21 · brand APO-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Apotex inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50975 · Verify on the e-Formulary ↗ (DIN 02231603)

Source record
DIN 02231603: Apo-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4083; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231603 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50975
Interchangeable products
Extra Strength Allergy Relief · DIN 02315955 · not recorded Jamp Cetirizine · DIN 02517566 · not recorded Jamp-Cetirizine · DIN 02451778 · not recorded Mar-Cetirizine · DIN 02427133 · not recorded Nat-Cetirizine · DIN 02496461 · not recorded Reactine · DIN 02223554 · not recorded
Shortage status: resolved shortage (ended 2020-12-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231603
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Extra Strength Allergy Relief · DIN 02315955 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Extra Strength Allergy Relief · DIN 02315955 Manufacturer: Pharmascience Inc.; listing date 2009-11-13 Health Canada: Marketed since 2012-09-24 · brand EXTRA STRENGTH ALLERGY RELIEF · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Pharmascience inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80148 · Verify on the e-Formulary ↗ (DIN 02315955)

Source record
DIN 02315955: Extra Strength Allergy Relief Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3938; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02315955 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80148
Interchangeable products
Apo-Cetirizine · DIN 02231603 · not recorded Jamp Cetirizine · DIN 02517566 · not recorded Jamp-Cetirizine · DIN 02451778 · not recorded Mar-Cetirizine · DIN 02427133 · not recorded Nat-Cetirizine · DIN 02496461 · not recorded Reactine · DIN 02223554 · not recorded
Shortage status: discontinued (2017-03-31, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02315955
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Cetirizine · DIN 02451778 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Cetirizine · DIN 02451778 Manufacturer: Jamp Pharma Corporation; listing date 2016-08-30 Health Canada: Marketed since 2026-03-05 · brand JAMP-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Jamp pharma corporation · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93812 · Verify on the e-Formulary ↗ (DIN 02451778)

Source record
DIN 02451778: Jamp-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4083; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02451778 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93812
Interchangeable products
Apo-Cetirizine · DIN 02231603 · not recorded Extra Strength Allergy Relief · DIN 02315955 · not recorded Jamp Cetirizine · DIN 02517566 · not recorded Mar-Cetirizine · DIN 02427133 · not recorded Nat-Cetirizine · DIN 02496461 · not recorded Reactine · DIN 02223554 · not recorded
Shortage status: active shortage (reported 2023-04-12, estimated to end 2023-12-31, last updated 2023-04-13) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02451778
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nat-Cetirizine · DIN 02496461 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Nat-Cetirizine · DIN 02496461 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-05-29 Health Canada: Marketed since 2020-08-20 · brand NAT-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Natco pharma (canada) inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98634 · Verify on the e-Formulary ↗ (DIN 02496461)

Source record
DIN 02496461: Nat-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id NAT Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4083; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496461 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98634
Interchangeable products
Apo-Cetirizine · DIN 02231603 · not recorded Extra Strength Allergy Relief · DIN 02315955 · not recorded Jamp Cetirizine · DIN 02517566 · not recorded Jamp-Cetirizine · DIN 02451778 · not recorded Mar-Cetirizine · DIN 02427133 · not recorded Reactine · DIN 02223554 · not recorded
Shortage status: resolved shortage (ended 2026-03-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02496461
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reactine · DIN 02223554 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Reactine · DIN 02223554 Manufacturer: McNeil Consumer Products Co.; listing date 2007-12-19 Health Canada: Marketed since 2026-03-12 · brand REACTINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Kenvue canada inc. · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Reactine: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43370 · Verify on the e-Formulary ↗ (DIN 02223554)

Source record
DIN 02223554: Reactine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id MCL Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02223554 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43370
Interchangeable products
Apo-Cetirizine · DIN 02231603 · not recorded Extra Strength Allergy Relief · DIN 02315955 · not recorded Jamp Cetirizine · DIN 02517566 · not recorded Jamp-Cetirizine · DIN 02451778 · not recorded Mar-Cetirizine · DIN 02427133 · not recorded Nat-Cetirizine · DIN 02496461 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02223554
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Cetirizine · DIN 02453363 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Cetirizine · DIN 02453363 Manufacturer: Apotex Inc.; listing date 2016-06-29 Health Canada: Marketed since 2016-04-22 · brand APO-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93991 · Verify on the e-Formulary ↗ (DIN 02453363)

Source record
DIN 02453363: Apo-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02453363 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93991
Interchangeable products
Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Reactine · DIN 01900978 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: resolved shortage (ended 2022-03-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02453363
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cetirizine · DIN 02515695 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cetirizine · DIN 02515695 Manufacturer: Sanis Health Inc.; listing date 2021-07-30 Health Canada: Marketed since 2025-08-08 · brand CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100508 · Verify on the e-Formulary ↗ (DIN 02515695)

Source record
DIN 02515695: Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id SAI Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02515695 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100508
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Reactine · DIN 01900978 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02515695
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cetirizine · DIN 02534126 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cetirizine · DIN 02534126 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-09-28 Health Canada: Marketed since 2023-07-20 · brand CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102306 · Verify on the e-Formulary ↗ (DIN 02534126)

Source record
DIN 02534126: Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id SIV Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534126 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102306
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Reactine · DIN 01900978 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02534126
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Cetirizine · DIN 02466171 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Cetirizine · DIN 02466171 Manufacturer: Jamp Pharma Corporation; listing date 2017-10-30 Health Canada: Marketed since 2025-12-15 · brand JAMP-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95446 · Verify on the e-Formulary ↗ (DIN 02466171)

Source record
DIN 02466171: Jamp-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id JPC Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466171 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95446
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Reactine · DIN 01900978 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: resolved shortage (ended 2022-06-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02466171
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Cetirizine · DIN 02512025 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Cetirizine · DIN 02512025 Manufacturer: Mantra Pharma Inc.; listing date 2021-11-30 Health Canada: Marketed since 2021-04-20 · brand M-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100119 · Verify on the e-Formulary ↗ (DIN 02512025)

Source record
DIN 02512025: M-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id MAT Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02512025 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100119
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Reactine · DIN 01900978 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02512025
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Cetirizine · DIN 02427141 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Cetirizine · DIN 02427141 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-10-29 Health Canada: Marketed since 2015-10-13 · brand MAR-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91167 · Verify on the e-Formulary ↗ (DIN 02427141)

Source record
DIN 02427141: Mar-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id MAR Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02427141 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91167
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Reactine · DIN 01900978 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: resolved shortage (ended 2018-06-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02427141
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Cetirizine Tablets · DIN 02530236 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
NRA-Cetirizine Tablets · DIN 02530236 Manufacturer: Nora Pharma; listing date 2023-05-31 Health Canada: Marketed since 2023-04-13 · brand NRA-CETIRIZINE TABLETS · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101942 · Verify on the e-Formulary ↗ (DIN 02530236)

Source record
DIN 02530236: NRA-Cetirizine Tablets Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id NRA Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02530236 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101942
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Reactine · DIN 01900978 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02530236
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Nat-Cetirizine · DIN 02496488 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nat-Cetirizine · DIN 02496488 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-05-29 Health Canada: Marketed since 2020-08-19 · brand NAT-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Natco pharma (canada) inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98635 · Verify on the e-Formulary ↗ (DIN 02496488)

Source record
DIN 02496488: Nat-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id NAT Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02496488 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98635
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Reactine · DIN 01900978 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: resolved shortage (ended 2026-03-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02496488
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Cetirizine · DIN 02315963 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Cetirizine · DIN 02315963 Manufacturer: Pharmascience Inc.; listing date 2008-12-23 Health Canada: Marketed since 2008-10-14 · brand PMS-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80149 · Verify on the e-Formulary ↗ (DIN 02315963)

Source record
DIN 02315963: PMS-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id PMS Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02315963 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80149
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded Reactine · DIN 01900978 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: resolved shortage (ended 2017-12-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02315963
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reactine · DIN 01900978 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Reactine · DIN 01900978 Manufacturer: McNeil Consumer Products Co.; listing date 2008-12-23 Health Canada: Marketed since 2026-04-17 · brand REACTINE 20 MG TABLET · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Kenvue canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Reactine: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=46803 · Verify on the e-Formulary ↗ (DIN 01900978)

Source record
DIN 01900978: Reactine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id MCL Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01900978 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=46803
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01900978
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Cetirizine · DIN 02528681 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Cetirizine · DIN 02528681 Manufacturer: Teva Canada Limited; listing date 2022-11-30 Health Canada: Marketed since 2023-02-24 · brand TEVA-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101788 · Verify on the e-Formulary ↗ (DIN 02528681)

Source record
DIN 02528681: Teva-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id TEV Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02528681 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101788
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Reactine · DIN 01900978 · not recorded
Shortage status: resolved shortage (ended 2024-09-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02528681
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Cetirizine · DIN 02517566 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2026-08-03 · checked 2026-09-02 · What does dormant mean?
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Cetirizine · DIN 02517566 Manufacturer: Jamp Pharma Corporation; listing date 2022-07-29 Health Canada: Dormant since 2026-08-03 · brand CETIRIZINE EXTRA STRENGTH · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Jamp pharma corporation · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100694 · Verify on the e-Formulary ↗ (DIN 02517566)

Source record
DIN 02517566: Jamp Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4083; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02517566 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100694
Interchangeable products
Apo-Cetirizine · DIN 02231603 · not recorded Extra Strength Allergy Relief · DIN 02315955 · not recorded Jamp-Cetirizine · DIN 02451778 · not recorded Mar-Cetirizine · DIN 02427133 · not recorded Nat-Cetirizine · DIN 02496461 · not recorded Reactine · DIN 02223554 · not recorded
Shortage status: resolved shortage (ended 2024-01-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517566
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-08-03 — choose a marketed DIN from the same-category list.

Mar-Cetirizine · DIN 02427133 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2022-05-04 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Cetirizine · DIN 02427133 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-10-29 Health Canada: Dormant since 2022-05-04 · brand MAR-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 10 MG · company Marcan pharmaceuticals inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91166 · Verify on the e-Formulary ↗ (DIN 02427133)

Source record
DIN 02427133: Mar-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000086; group id 2; item number 0003; lccId None; manufacturer id MAR Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.4083; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02427133 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91166
Interchangeable products
Apo-Cetirizine · DIN 02231603 · not recorded Extra Strength Allergy Relief · DIN 02315955 · not recorded Jamp Cetirizine · DIN 02517566 · not recorded Jamp-Cetirizine · DIN 02451778 · not recorded Nat-Cetirizine · DIN 02496461 · not recorded Reactine · DIN 02223554 · not recorded
Shortage status: resolved shortage (ended 2020-03-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02427133
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2022-05-04 — choose a marketed DIN from the same-category list.

Jamp Cetirizine Tablets · DIN 02517353 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2026-08-03 · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Cetirizine Tablets · DIN 02517353 Manufacturer: Jamp Pharma Corporation; listing date 2022-05-31 Health Canada: Dormant since 2026-08-03 · brand JAMP CETIRIZINE TABLETS · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100677 · Verify on the e-Formulary ↗ (DIN 02517353)

Source record
DIN 02517353: Jamp Cetirizine Tablets Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id JPC Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02517353 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100677
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Reactine · DIN 01900978 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: resolved shortage (ended 2025-12-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517353
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-08-03 — choose a marketed DIN from the same-category list.

Mint-Cetirizine · DIN 02491125 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2023-01-22 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Cetirizine · DIN 02491125 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-02-28 Health Canada: Dormant since 2023-01-22 · brand MINT-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98114 · Verify on the e-Formulary ↗ (DIN 02491125)

Source record
DIN 02491125: Mint-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id MIN Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02491125 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98114
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded NRA-Cetirizine · DIN 02521806 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Reactine · DIN 01900978 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02491125
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2023-01-22 — choose a marketed DIN from the same-category list.

NRA-Cetirizine · DIN 02521806 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-18 — choose a marketed DIN from the same-category list.Discontinued 2023-07-18 · checked 2026-09-20
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-07-18 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
NRA-Cetirizine · DIN 02521806 Manufacturer: Nora Pharma; listing date 2022-05-31 Health Canada: Cancelled post market since 2023-07-18 · brand NRA-CETIRIZINE · ATC R06AE07 CETIRIZINE · form Tablet · route Oral · ingredients CETIRIZINE HYDROCHLORIDE 20 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101099 · Verify on the e-Formulary ↗ (DIN 02521806)

Source record
DIN 02521806: NRA-Cetirizine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 040000087; group id 2; item number 0004; lccId None; manufacturer id NRA Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7535; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02521806 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101099
Interchangeable products
Apo-Cetirizine · DIN 02453363 · not recorded Cetirizine · DIN 02515695 · not recorded Cetirizine · DIN 02534126 · not recorded Jamp Cetirizine Tablets · DIN 02517353 · not recorded Jamp-Cetirizine · DIN 02466171 · not recorded M-Cetirizine · DIN 02512025 · not recorded Mar-Cetirizine · DIN 02427141 · not recorded Mint-Cetirizine · DIN 02491125 · not recorded NRA-Cetirizine Tablets · DIN 02530236 · not recorded Nat-Cetirizine · DIN 02496488 · not recorded PMS-Cetirizine · DIN 02315963 · not recorded Reactine · DIN 01900978 · not recorded Teva-Cetirizine · DIN 02528681 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02521806
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-07-18 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (04:00 ANTIHISTAMINES) and how they are covered

Matched class: 04:00 ANTIHISTAMINES

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 04:00 ANTIHISTAMINES

BILASTINE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg/mL, 20mg · Oral Sol, Tab

LORATADINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab

RUPATADINE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 04:00
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Adults and children 12 years of age and over: REACTINE® 20 mg Tablet (cetirizine hydrochloride) is indicated: • for the fast relief of nasal and non-nasal symptoms associated with seasonal and perennial allergic rhinitis (i.e. sneezing, rhinorrhea, post-nasal discharge, nasal congestion/stuffiness, tearing and redness of the eyes, itchy nose/throat) and chronic idiopathic urticaria (e.g. pruritus and hives). 1.1 Pediatrics Pediatrics - Children <12 years of age: REACTINE® 20 mg Tablet is not recommended in children less than 12 years of age, as safety and efficacy have not been established in this age group. 1.2 Geriatrics Geriatrics: Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness and a brief discussion can be found in the appropriate sections (See Warning and Precautions, Special Populations- Geriatrics). REACTINE® 20 mg Tablet is not recommended in patients 65 years and older. The recommended starting dose is 5 mg once daily. https://pdf.hres.ca/dpd_pm/00084353.PDF PM date: APR 17, 2026 Source product: REACTINE 20 MG TABLET; DIN 01900978; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Extra Strength Allergy Relief · DIN 02315955 Shortage status: discontinued (2017-03-31, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02315955

Check this DIN again

Jamp-Cetirizine · DIN 02451778 Shortage status: active shortage (reported 2023-04-12, estimated to end 2023-12-31, last updated 2023-04-13) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02451778

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Apo-Cetirizine, Extra Strength Allergy Relief, Jamp-Cetirizine, Nat-Cetirizine, Reactine, Cetirizine, M-Cetirizine, Mar-Cetirizine, NRA-Cetirizine Tablets, PMS-Cetirizine, Teva-Cetirizine, Jamp Cetirizine, Jamp Cetirizine Tablets, Mint-Cetirizine, NRA-Cetirizine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026